Tag: ERT

Stories

The standard of care for Canadians with Gaucher disease just changed. The drug costs per patient per year will be reduced by about $100,000 and it is all due to the pan-Canadian Pharmaceutical Agency (pCPA).

Results from a new survey, published in the OJRD, shows that ERT [Lumizyme (alglucosidase alfa), also known as Myozyme outside of the US] for patients with late-onset Pompe disease significantly reduces the risk of them becoming wheelchair dependent, but did not reduce the need for respiratory assistance.